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This study explored patients’ perspectives about taking the new direct-acting 
antivirals (DAAs) for the treatment of Hepatitis C (i.e., sofosbuvir, simeprevir, 
ledipasvir/sofosbuvir, ombitasvir/paritraprevir/ritonavir and dasabuvir) to 
identify facilitators of medication adherence. The project was conducted using 
semi-structured interviews with 12 Veterans who successfully completed a 
treatment course on the new DAAs. The Veterans were recruited using 
purposive sampling. The data collected from the semi-structured interviews was 
analyzed using an adapted open coding method outlined by Auerbach and 
Silverstein (2003), with identification of relevant text sub-grouped into 
repeating ideas, and then creation of overarching themes and constructs. 
Results obtained provide insight into factors that influenced the Veterans’ 
medication adherence during the course of treatment. Key constructs, 
embodying major themes supported by repeating ideas, included recognizing 
the “burden of HCV,” the importance of the “treatment engagement process,” 
and anticipation of “positive outcomes.” Clinical implications are discussed.  
Keywords: Hepatitis C, Adherence, Health Care, Health Behavior, Progressive, 
Quality of Life, Qualitative Research, Semi-Structured Interviews  
  
Hepatitis C virus (HCV) is a widely recognized public health concern in the United 
States (Centers for Disease Control and Prevention [CDC], 1998; Edlin et al., 2001; Evon et 
al., 2013; Lawitz et al., 2013; Ly et al., 2012; Moyer, 2013; Sloan, Straits-Troster, Dominitz, 
& Kivlahan, 2004; Veterans Health Administration, 2015).  It is the most common chronic 
blood borne infection in this country (Alter, 1999; CDC, 2011), particularly in the Veteran 
population.  Globally, about 185 million individuals are infected with HCV, which is a 
seroprevalence rate of HCV of 2.8% (Hanafiah, Groeger, Flaxman, & Wiersma, 2013).  While 
in the general US population, prevalence of HCV is estimated at 1.8% (CDC, 1998), the 
prevalence among Veterans enrolled in the Veterans Healthcare Administration (VHA) is much 
higher, ranging between 8% - 10% (CDC, 1998; Lawitz et al., 2013; Ly et al., 2012; Sloan et 
al., 2004; Slomski, 2014).  VHA is the largest HCV care provider in the United States, serving 
between 174,000 and 180,000 Veterans between 2009 and 2013 (Veterans Health 
Administration, 2015).   The consequences of chronic HCV infection are well known and 
mainly consist of cirrhosis and hepatocellular carcinoma that lead to increased healthcare costs 
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and an increased mortality.  Projected medical costs for treating HCV between 2010 and 2019 
could reach $10.7 billion in direct care and a $54.2 billion societally (Wong, McQuillan, 
McHutchison, & Poynard, 2000).  HCV has now surpassed human immunodeficiency virus as 
a leading cause of death in the United States (Rustgi, 2007). 
 
New Direct-Acting Antivirals for HCV 
 
New US Food and Drug Administration (FDA) approved direct-acting antivirals 
(DAAs) (specifically, sofosbuvir, simeprevir, the combination ledipasvir/sofosbuvir, and the 
combination ombitasvir/paritraprevir/ritonavir and dasabuvir) became available to patients in 
2014 at a cost between $66,000 and $84,000 per person for a 12-week course (Brennan & 
Shrank, 2014; Lawitz et al., 2013; Reau & Jensen, 2014; Slomski, 2014; Steinbrook & 
Redberg, 2014; Veterans Health Administration, 2015).  Some patients who have cirrhosis need 
a 24-week course of these medications (American Association for the Study of Liver Diseases 
and the Infectious Diseases Society of America, 2015; Veterans Health Administration, 2015).  
Compared to traditional interferon-based treatment regimens for Hepatitis C (HCV), these new 
medications have many benefits.  One such benefit is that the new medications to treat HCV 
have a much lower side effect profile (e.g., less nausea/vomiting, dizziness, depression, sleep 
problems, skin reactions, headaches, fatigue, flu-like symptoms).  Another advantage to taking 
the new medications is the reduced treatment length and better cure rates (8-24 weeks with a 
cure rate of 80% to over 90% instead of about 48 weeks with a 45-75% cure rate with 
interferon-based regimens, depending on a person’s genotype [Brennan & Shrank, 2014; 
Lawitz et al., 2013; Reau & Jensen, 2014; Steinbrook & Redberg, 2014]).  Lastly, the non-
interferon based treatments are all oral (pills) administration instead of subcutaneous self-
injections combined with orally administered medications.  The medication prescribed and 
lengths of treatment are dependent on a thorough assessment of the person’s HCV history (e.g., 
genotype, whether they have cirrhosis, prior HCV treatment, hepatocellular carcinoma [HCC], 
HIV co-infection).  Patients are considered “cured” when the virus is undetectable in their 
blood three months after treatment completion. 
 
Guidelines for Treatment 
 
The Veterans Health Administration (VHA) has established treatment guidelines for 
the new HCV medications (Veterans Health Administration, 2015), that require a thorough 
pre-treatment assessment to identify mainly the patient’s HCV genotype, viral load, stage of 
liver disease (presence or absence of advanced fibrosis/cirrhosis), presence of hepatocellular 
carcinoma, HIV co-infection, details of past HCV treatment, and mental health and substance 
abuse issues or cognitive limitations that could affect treatment adherence.  Furthermore, the 
guidelines emphasize that HCV treatment must incorporate strategies to measure and support 
adherence to the HCV treatment regimen, given the heightened cost of treatment and Veterans’ 
expectations for being cured (Slomski, 2014).  At the VHA facility where the study took place, 
Veterans are required to attend an HCV Education Class (that describes, among other topics, 
natural history of HCV, available therapies, candidates for therapy) and an interview with a 
health psychologist. 
  Treatment guidelines for HCV in the US private sector have been somewhat different 
from VHA.  For individuals receiving HCV treatment in the private sector, insurance 
companies have set up barriers for treatment, including limiting access to DAAs only to the 
most seriously ill patients as a result of the high cost of these medications.  In contrast, most 
Veterans receiving HCV care through VHA are eligible for treatment with DAAs.  In addition, 
VHA receives a 40 percent financial discount on the DAAs from pharmaceutical companies.  
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The DAA treatment supports within VHA (e.g., education class, health psychology 
assessment) are largely not required in the private sector. Outside the US, pharmaceutical 
companies have tiered pricing to make these medications more affordable in developing 
countries, where medication pricing is often negotiated with governments (e.g., 10 dollars 
instead of up to 1000 dollars per pill; American Association for the Study of Liver Diseases 
and the Infectious Diseases Society of America, 2015; Philpott, 2014; Vann & Marcellin, 
2015). 
 
HCV Medication Adherence 
 
The World Health Organization (2003) defines treatment adherence as “the extent to 
which as person’s behavior – taking medication, following a diet, or making healthy lifestyle 
changes – corresponds with agreed-upon recommendations from a health-care provider” (p. 
17).  More specifically, medication adherence is defined as the patient’s conformance with the 
provider’s recommendation with respect to timing, dosage, and frequency of medication-taking 
during the prescribed length of time in order to produce a therapeutic result (World Health 
Organization, 2003).  Unfortunately, approximately 20-30% of all medication prescriptions are 
not filled consistently, and nearly 50% of medications prescribed for chronic illnesses are not 
taken as prescribed (Brown & Bussell, 2011; Fischer et al., 2011; World Health Organization, 
2003).  The direct cost of medication non-adherence to the United States health care system is 
estimated at $100 billion to $289 billion per year (Osterberg & Blaschke, 2005; World Health 
Organization, 2003).   
Poor adherence to new HCV medications can similarly be expected to negatively 
impact healthcare cost and treatment outcome, given their expense and high adherence 
requirements for efficacy. Published research on interferon-based treatment regimens for HCV 
indicated that treatment response was directly affected by how closely the medication regimen 
was followed (Smith et al., 2007).  A person is more likely to achieve a cure with at least 85% 
adherence to the medication regimen (DiMatteo, Giordani, Lepper, & Croghan, 2002; Evon et 
al., 2013; Lo Re III et al., 2009).  Additionally, poor adherence to new DAAs may lead to the 
development of resistance to antiviral therapies. 
To our knowledge, there has been no published research on factors that facilitate 
adherence to the new HCV medication regimens.  Published literature on adherence to 
interferon-based treatment regimens, however, point to several facilitative factors, including: 
the absence of pre-existing psychiatric or substance use disorder, early detection, intervention, 
and at least a one month period of total abstinence from substances prior to treatment initiation, 
integrating the HCV medical care with mental health and substance abuse services, 
implementing necessary support services (e.g., case management, transportation, housing), 
establishing rapport in the physician-patient relationship, providing adequate education to 
patients on potential effects of the medications, and developing patients’ positive pre-existing 
beliefs about the treatment (Edlin et al., 2001; Edlin et al., 2005; Gatti, Jacobson, Gazmararian, 
Schmotzer, & Kripalani, 2009; Martin-Santos et al., 2008; Neame & Hammond, 2005; 
Sylvestre & Clements, 2007).   
The purpose of this study was to identify factors that promote adherence to the new 
non-interferon based HCV medications among Veterans.   The study originated when the VHA 
Chief of the Digestive Diseases Service (third author) contacted the Chief of the Psychology 
Service (fourth author) to form a team with her to better understand factors that would support 
Veterans’ HCV medication adherence to achieve cure and improve health outcomes. The first 
author, who worked as a health psychology fellow in the Digestive Diseases Service, and the 
second author, who had qualitative research and integrated primary care/mental health clinical 
expertise, joined the team for this project. Currently, all four authors work at VHA in various 
Nicole Giordano, Anthony Brinn, Guadalupe Garcia-Tsao, and Steve Martino                          187 
clinical, administrative, and research capacities to support health-related behavior change 
among patients who receive medical services in primary care and specialty medical settings. 
 
Methods 
 
This study involved the use of a semi-structured interview and qualitative analysis of 
the experiences of Veterans living with HCV who successfully completed their prescribed non-
interferon based DAAs.  The study was conducted between January and October 2015. No 
prior published research had identified factors that facilitate adherence to the new HCV 
medication regimens.  Thus, the authors took a naïve perspective and used a grounded theory 
qualitative approach in order to better understand the Veterans personal experiences taking 
these medications.  This approach allows for a more open-ended exploration of the participants’ 
perspectives.  Moreover, grounded theory allows for the construction of a theoretical 
explanation for the findings that could set the foundation for future research on HCV 
medication adherence (Strauss & Corbin, 2000). 
 
Recruitment 
 
Following review and approval by the local Veterans Administration Institutional 
Review Board, Liver Clinic medical staff at a local VHA in the Northeast United States 
examined the Veterans’ VHA electronic health records and identified 29 HCV-positive 
Veterans who had completed a workup to assess candidacy for DAA therapy (including an 
HCV Education Class and appointment with a health psychologist), had completed a DAA 
treatment regimen for HCV, and were actively engaged in outpatient treatment services within 
the Liver Clinic.   These Veterans were mailed an opt-out letter, which requested that they call 
the research team to indicate if they did not want to participate in the study. If they did not 
respond within 10 days, the research team contacted them by telephone to describe the study 
and invite them to participate.  One opted out.  Attempts were made to reach the all remaining 
28 Veterans by telephone, including leaving voicemail messages when unavailable.  Twelve 
Veterans agreed to participate in the study, two Veterans declined participation, and 14 were 
not reached. The 12 participants subsequently attended an individual session with research 
personnel to complete the verbal informed consent process involving a review of an 
information form that outlined the study’s purpose, voluntary nature of participation, and 
potential risks/benefits.  
 
Study Participants 
 
Participants in this study were 12 male Veterans.  They were mostly Caucasian (92%), 
on average about 64 years old, single or divorced (75%), retired or disabled (75%), and from a 
variety of military backgrounds during the Vietnam era (75%).  Course of prescribed DAA 
therapy completed by the participants were as follows:  12-week course = 9 (75%); 16-week 
course = 1 (8%); 24-week course = 2 (17%). All participants had undetectable HCV viral loads 
at the time of semi-structured interviews.  They all had multiple medical and mental health 
comorbidities.  Two-thirds of the sample had a history of high adherence to prescribed 
medications and one-third of the sample had a history of medium to low adherence to 
prescribed medications (see Table 1).   
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Table 1.  Demographic Characteristics. 
Variable 
Male, n (%) 
 
12 (100%) 
Ethnicity, n (%) 
     Caucasian 
     Hispanic 
 
11 (92%) 
1 (8%) 
Age, m (SD) 63.9 (5.5) 
Education, n (%) 
     High School 
     Some College 
     BA 
     Unspecified 
 
4 (33%) 
4 (33%) 
2 (17%) 
2 (17%) 
Marital Status, n (%) 
     Single 
     Married  
     Divorced 
 
4 (33%) 
3 (25%) 
5 (42%) 
Household Composition, n 
(%) 
     No other residents      
     One person 
     Two people 
 
5 (42%) 
4 (33%) 
3 (25%) 
Residence in Miles from 
VHA, m (SD) 
34.9 (29.37) 
Employment Status, n (%) 
     Employed 
     Unemployed 
     Retired 
     Disabled 
 
1 (8%) 
2 (17%) 
5 (42%) 
4 (33%) 
Branch of Military, n (%) 
Army 
Marine Corps 
Navy 
 
4 (33%) 
2 (17%) 
4 (33%) 
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Air Force 
Marine Corps and Army 
1 (8%) 
1 (8%) 
Service Connection, n (%) 6 (50%) 
Era of Service, n (%) 
     Vietnam 
     Post-Vietnam 
 
9 (75%) 
3 (25%) 
Combat Exposure, n (%) 5 (42%) 
Military Sexual Trauma, n 
(%) 
0 (0%) 
Current Medical Diagnoses, 
n (%) 
     Diabetes 
     Obesity (BMI>30) 
     Hypertension 
     Cirrhosis 
     Varices 
     Enchephalopathy 
     Hepatocellular Carcinoma 
     Other Cancers 
 
4 (33.3%) 
3 (25%) 
7 (58.3%) 
4 (33.3%) 
2 (16.7%) 
1 (8.3%) 
1 (8.3%) 
2 (16.7%) 
HIV Infection, n (%) 
Detectable HCV Viral Load, 
n (%) 
1 (8.3%) 
0 (0%) 
Active Mental Health 
Diagnosis, n (%) 
     Depression 
     PTSD 
     Bipolar 
 
5 (42%) 
3 (25%) 
1 (8.3%) 
Current Mental Health 
Treatment, n (%) 
5 (42%) 
Active Substance Use 
Disorder, n (%) 
1 (8.3%) 
Current Substance Abuse 
Treatment, n (%) 
2 (16.7%) 
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History of IV Drug Use, n 
(%) 
7 (58%) 
Past 30 Days Outpatient 
Clinic Attendance, m (SD) 
     Medical 
     Mental Health 
     Substance Use 
 
1.9 (1.4) 
0.5 (0.7) 
0.2 (0.4) 
Morisky Adherence 
Category, n (%) 
     High Adherence 
     Medium Adherence 
     Low Adherence 
 
8 (66.7%) 
1 (8.3%) 
3 (25%) 
Note.  For the Current Medical Disorders category, 
the percentages exceed 100% because patients could 
have multiple medical comorbidities.  For Morisky 
prescribed medication adherence scores, 
interpretation is as follows: 0 = high adherence; 1-2 = 
medium adherence; and 3 or more = low adherence. 
 
The Semi-Structured Interview 
 
All authors developed a semi-structured interview to obtain information about factors 
that influenced Veterans’ adherence to the new HCV medications.  Questions were open-ended 
and designed to elicit perspectives on the experience of living with HCV, being on the new 
medications to treat HCV, managing challenges throughout their treatment, and completing a 
course of treatment for HCV (see Table 2).  The interview was developed successively: (1) the 
first author initially drafted questions based on a literature review of issues affecting medication 
adherence and in consultation with the Liver Clinic staff; (2) co-authors reviewed and edited 
questions to target areas of interest for this study, while minimizing suggestion in questioning; 
and (3) the first author conducted mock interviews with Liver Clinic staff to eliminate 
redundant items and finalize wording. 
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Table 2.  Semi-structured Interview. 
1) What has it been like for you to have Hepatitis C? 
 
2) Why did you choose to receive the new treatment for your Hepatitis C? 
 
3) What has been your experience being on the new medications for Hepatitis C? 
 
4) Why did you choose to stay on the medication and complete treatment? 
 
5) What were some challenges you experienced along the way while you were on the medication? 
 
a. What, if any, side effects did you experience that you attribute to the Hepatitis C 
medication? 
 
b. How did you overcome them? 
 
6) What helped you with your decision to stay on the medication? 
 
7) What does it mean for you to have completed this course of treatment? 
 
8) What do you think we can do to help patients increase their likelihood of completing treatment? 
 
9) What else would be important for me to know in order to get the best understanding of why you 
completed Hepatitis C treatment? 
 
Morisky Medication Adherence Questionnaire 
 
This 8-item, self-report measure of patient adherence to prescribed medications 
(Morisky, Ang, Krousel-Wood, & Ward, 2008) was administered to participants following 
their completion of the semi-structured interview.  It has been applied to a broad range of 
medications used to treat chronic illnesses and to various cultures (Al-Qazaz et al., 2010; Korb-
Savoldelli et al., 2012; Morisky, Ang, Krousel-Wood, & Ward, 2008) and has been shown to 
be a reliable (α=.83) measure with good concurrent and predictive validity (Bailey et al., 2012; 
Morisky, Ang, Krousel-Wood, & Ward, 2008; Reynolds et al., 2012).  A total score is 
interpreted as follows: 0 = high adherence; 1-2 = medium adherence; and 3 or more = low 
adherence.   
 
Semi-Structured Interviewing 
 
After providing consent, Veterans completed the semi-structured interview about their 
experiences with taking the new HCV medications.  The first author conducted the interviews 
using a semi-structured format to guide the line of inquiry (see Table 2).  The interviewer 
adopted a non-leading style and used open-ended questions to probe for elaboration about 
factors influencing the participants’ medication adherence.  During the interview process, the 
first author took brief manual notes while the participants responded as a means to highlight 
words of interest for further inquiry.  Information about the participants’ demographic 
background, medical issues, and mental health /substance use history was extracted from the 
electronic health record following the semi-structured interview.  All interviews were audio 
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recorded and took about one hour to complete.  The first author transcribed all of the recorded 
interviews.  These interviews were conducted until there was a saturation of data. 
 
Qualitative Data Analysis 
 
All interviews were coded using an adapted coding method outlined by Auerbach and 
Silverstein (2003), rooted in grounded theory as described by Strauss and Corbin (2000).  The 
first and second authors coded and thematically analyzed the interview transcripts. First, each 
author independently identified relevant text (i.e., Veterans’ reasons for adherence to the new 
HCV medications, factors that facilitated their adherence, and how they successfully managed 
barriers that arose during their trial), subgrouped the relevant text into repeating ideas (i.e., 
participants’ use of similar words or sentences to convey the same idea), and coded them within 
the transcripts.  The authors conducted this open coding line-by-line for all transcripts.  
Afterward, the authors compared their coding, resolved discrepancies, and identified 
overarching themes from the repeating ideas that describe the Veterans’ subjective experiences.  
Next, they categorized themes into theoretical constructs, which function to tie qualitative data 
to overarching frameworks through which to understand results.    The last author reviewed the 
identified repeating ideas, themes, and constructs across four transcripts he randomly selected 
from the complete set of 12 and confirmed their presence. Finally, the first author calculated 
the percentage of participant interviews in which each theme and repeating idea was present. 
 
Results 
 
Three theoretical constructs, nine themes, and 28 repeating ideas (italicized in text 
below) were identified within the transcripts and coded.  Table 3 lists the percentage of 
participant interviews in which each theme and repeating idea was present. 
 
Table 3.  Theoretical Constructs, Themes, and Repeating Ideas. 
 
TC 1: Burden of HCV 
T 1: Chronic Illness with Chronic Negative Impact (100%) 
     RI 1: “I’m Not Healthy” (100%) 
     RI 2: “It’s Always in the Back of Your Mind” (83.3%) 
     RI 3: Stigma (50%) 
     RI 4: Interactions Between Mental Health and Substance Use Disorders (25%) 
T 2: Knowledge is Power (100%) 
     RI 5: Course of HCV and Its Consequences (91.7%) 
     RI 6: Pros/Cons to New Non-Interferon Versus Interferon-Based Treatments 
     (75%) 
TC 2: Treatment Engagement Process 
T 3: Treatment as “No Brainer” (100%) 
     RI 7: Realistic Hope for Cure (100%) 
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     RI 8: “I Want to be Healthy” (100%) 
     RI 9: Improved Quality of Life (83.3%) 
T 4: Easy Treatment (91.7%) 
     RI 10: Simplicity of Regimen (91.7%) 
     RI 11: Clear End to Treatment (41.7%) 
     RI 12: Manageability of Side Effects (83.3%) 
     RI 13: Availability of Medications (83.3%) 
     RI 14: Aversion to Interferon (83.3%) 
T 5: Provider Facilitation of Treatment (83.3%) 
     RI 15: Clear and Honest Communication (58.3%) 
     RI 16: Rapport with Providers (50%) 
     RI 17: Trust for Provider Expertise (83.3%) 
T 6: Patient Facilitation of Treatment (100%) 
     RI 18: Routine for Medication Adherence (75%) 
     RI 19: Commitment to Behavioral Strategies for Managing Side Effects (91.7%) 
     RI 20: Self-encouragement (75%) 
     RI 21: Determination to Complete Treatment (100%) 
T 7: Social/Economic Facilitation of Treatment (58.3%) 
     RI 22: Supports are Key (50%) 
     RI 23: Cost is Important 
TC 3: Positive Outcomes 
T 8: “I’m Free” (75%) 
     RI 24: “I Don’t Have to Worry Anymore” (58.3%) 
     RI 25: “A New Lease on Life” (58.3%) 
T 9: System Variables in New HCV Treatment (83.3%) 
     RI 26: Satisfaction with the VHA System (50%) 
     RI 27: “The VA Saved My Life” (58.3%) 
     RI 28: Areas in Need of Improvement (66.7%) 
Note.  TC = Theoretical Constructs; T = Themes; RI = Repeating Ideas. 
 
Theoretical Construct 1: Burden of HCV 
 
Theme 1: Chronic Illness with Chronic Negative Impact (100%).  All Veterans 
discussed their concerns about how HCV progressively impaired their health and would be 
fatal without treatment.  (“I’m not healthy” [100%]).  Veteran’s spoke in detail about how their 
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poor health negatively affected their lives physically, emotionally, and socially (e.g., “I wanted 
to get rid of the virus.  I want to have a healthy, normal life.”). 
Most Veterans noted how “[HCV is] always in the back of your mind” (83.3%).  They 
emphasized the psychological distress of HCV, even in the absence of physical symptoms (e.g., 
“It’s a burden in itself… you know you’re sick you’re always waiting for the other foot to come 
down”). 
The stigma of living with HCV emerged as a prevalent theme (50%).  Participants 
discussed how HCV impaired their social functioning and relationships (e.g., “Stigmatized… 
they think that they’re going to catch it if they come in contact with me, like AIDS or 
something”). 
Some participants (25%) talked about the negative interactions between mental health 
and substance use disorders and how having HCV worsened these conditions (e.g., “[HCV] 
affected me in all ways…mentally, physically… it was just very stressful…it was wearing on 
my whole body”). 
 Theme 2: Knowledge is Power (100%).  Veterans identified knowing about the course 
of HCV and its consequences (91.7%) as an important consideration for taking the new non-
interferon based HCV medications.  They identified the deleterious progression of HCV, its 
specific effects on the liver, and what might happen without treatment (e.g., “Knowing it’s 
[HCV]…destroying and scarring up my liver…it’s unhealthy, it carries a death sentence”). 
 Knowledge about the pros/cons of the new non-interferon versus interferon-based 
treatments factored into the participants’ decision to adhere to their medication regimens 
(75%).  Veterans recognized the advantages of the new HCV medications compared to the 
drawbacks of the interferon-based treatments, such as length of treatment, flu-like side effects, 
and self-injections (e.g., “The liver specialist…advised that ‘if it was me, I wouldn’t take 
[interferon], because I believe that there are some medications in the system that would treat 
you better’… he said ‘your Hepatitis C ain’t that bad, I would wait until something better comes 
in the pipeline’”). 
 In summary, living with progressive HCV is burdensome to Veterans physical, 
psychological, and social well-being.  Reflecting Veterans’ specific burdens in juxtaposition 
with information about the many benefits of DAAs (e.g., high cure rates, ease of administration, 
low side-effect profile) could promote greater HCV medication adherence 
 
Theoretical Construct 2: Treatment Engagement Process 
 
Theme 3: Treatment as “No Brainer” (100%).  All participants wanted effective 
treatment for their HCV.  They spoke about the new medication giving them a realistic hope 
for cure (100%).  Through their own investigation and in discussions with providers, Veterans 
decided the new treatment’s high cure rate made adherence an obvious choice (e.g., “I was 
optimistic that I would be cured… that helped a lot”).  In addition, all Veterans reported “I 
want to be healthy” and saw adherence to the new HCV medications as critical to that goal.  A 
large portion of Veterans also talked about how treating their HCV could give them an 
improved quality of life (83.3%). 
 Theme 4: Easy Treatment (91.7%).  The majority of the Veterans commented on the 
relative simplicity of the regimen (91.7%) for the new HCV medications, which promoted their 
treatment adherence.  Participants liked the pill form and having clear instructions (e.g., “The 
protocol is so simple… it’s effortless”). 
 Some participants liked having a clear end to treatment (41.7%).  They discussed how 
the clear and specific timeframe for the treatment allowed them to count down their days of 
treatment (e.g., “When you’re on this medicine, you have to understand that there’s an end to 
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it eventually…it’s only a temporary treatment for a longer lasting result”), and this bolstered 
their adherence. 
 Several Veterans commented how the manageability of side effects (83.3%) helped 
them adhere to the new HCV medications.  None of the participants reported any significant 
side effects that hampered their ability to complete treatment.  Some reported mild physical 
side effects, which they managed independently or with the help of providers (e.g., “It’s not 
that bad at all, this new medication… side effects were manageable”). 
 Most Veterans appreciated the availability of medications (83.3%).  They discussed 
how VHA made the new medications easily available to them, and this availability promoted 
their desire to begin and complete the treatment protocol (e.g., “It [new HCV treatment] was 
available… they [the VHA] said ‘would you… be interested in trying it?’ so of course I 
am…who wants to continue being sick?”).  
 Many participants commented how their own or others’ past negative treatment 
experiences with interferon-based regimens gave them an aversion to interferon (83.3%).  
Veterans said these experiences made waiting for the new medications worthwhile and 
motivated adherence (e.g., “After the interferon…this [new HCV treatment] was…sweet 
sailing… this is like taking aspirin…I kept wondering, is this going to do any good…I don’t 
feel anything”). 
 Theme 5: Provider Facilitation of Treatment (83.3%).  Veterans highlighted the 
importance of provider facilitation of treatment.  Veterans noted that clear and honest 
communication (58.3%) helped their medication adherence (e.g., “Conversations…were 
straight forward, professional, to the point, answered all my questions, and I felt very 
comfortable and that’s what led me to proceed with the medication”).  Having rapport with 
providers (50%) also mattered to Veterans, particularly in the context of a preexisting positive 
patient-provider relationship (e.g., “I had a pretty good relationship with my doctor…I had 
been seeing him a little while…we had a little rapport”). 
 Veterans talked about having trust for provider expertise (83.3%).  They respected their 
providers as knowledgeable medical professionals and followed their HCV treatment advice 
(e.g., “I believe that it’s important for me to work with my providers to ensure the best possible 
results in maintaining a good state of health.  I do my part; I can’t do the medical part with 
limited knowledge and limited access to whatever’s necessary, so I trust the system”). 
 Theme 6: Patient Facilitation of Treatment (100%).  Patient’s also engaged in 
behaviors that supported their medication adherence.  Three-fourths of the sample reported that 
establishing a routine for medication adherence was helpful.  Participants described integrating 
the HCV medication regimen into their preexisting daily routines (e.g., “I arranged it so I take 
a thyroid medication first thing in the morning …every day and then I would take the 
medication…at the same time”). 
 Moreover, most Veterans made a commitment to behavioral strategies for managing 
side effects (91.7%).  Veterans spoke about how they attempted to cope with medication side 
effects by trying strategies recommended by providers or other patients (e.g., “I’m a very 
impatient person to begin with, but that…multiplied…when I was on that stuff [new HCV 
medication]. I really had to count to 10 a lot…I’ve got calendars…I got a pad on my desk and 
I write down everything.”). 
 Veterans typically used self-encouragement to promote adherence (75%) (e.g., “I can 
do this.” or “It was only the last two weeks of the program and I kept saying to myself, you 
only got two more weeks on it, just do it… I had a countdown… all of a sudden… I was right 
at the end of it”).  Veterans reported that this self-encouragement gave them determination to 
complete treatment using all available resources during treatment (e.g., “I was determined to 
do it.”). 
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 Theme 7: Social/Economic Facilitation of Treatment (58.3%).  Veterans reported 
that supports are key (58.3%) to success.  Veterans talked about how outside support from 
family and friends helped them to begin the regimen, cope, adhere, and complete the regimen 
(e.g., “[My wife’s] always been there to push…my wife handles most of the medication.”).  In 
addition, some Veterans spoke about how cost is important (25%) and that knowledge of how 
costly the new medications are made them more motivated for adherence (e.g., “I think the VA 
hospital has been more than kind in asking me to do this…I know how expensive it is and I 
appreciate it and I just wanted to go along with their program.”). 
 These seven themes underscore factors that could better engage Veterans in their HCV 
treatment. Veterans’ adherence to DAAs could be maximized by emphasizing their realistic 
hope for cure and expectations for an improved quality of life given the effectiveness of these 
medications and their simple, clearly delineated regimens.  Moreover, teaching Veterans 
strategies to improve medication adherence, facilitating collaborative patient-provider working 
relationships that foster trust, and leveraging extant social supports could further support 
Veterans’ efforts to take their HCV medication regimens as prescribed over the full course of 
treatment. 
 
Theoretical Construct 3: Positive Outcomes 
 
Theme 8: “I’m Free” (75%).  Veterans said “[they] don’t have to worry anymore” 
(58.3%) about being HCV positive and reported a decrease in psychological distress and 
anxiety following the completion of the medication trial (e.g., “Knowing that…Hepatitis C is 
at a level where it’s not traceable, it can give me peace of mind…put my mind at ease, one less 
thing to worry about.”).   
 Many Veterans felt they had “a new lease on life” (58.3%) following treatment 
completion.  They noted having improved relationships and social functioning and discovering 
new purpose and value in life (e.g., “I’ve been given a new lease on life… it helped me to be 
more mindful of how I attended to my day-to-day… with nutrition, exercise… supports, a 
refinement of my values and a sense of… purpose”). 
 Theme 9: System Variables in New HCV Treatment (83.3%).  Participants 
identified how VHA had successfully established a treatment-accessible system for Veterans 
to receive the new HCV medication.  Half of participants reported relative satisfaction with the 
VHA system.  Veterans talked about how the structure implemented in the Liver Clinic helped 
them adhere to treatment (e.g., “I was at the hospital every two weeks and that was important 
because… I kept up with my medication… they… guide you… sometimes you’re on a 
medicine that can have an effect on your mind, you can tend to stop taking the medicine or you 
don’t take it properly and that can affect the outcome”). 
 More than half of the Veterans felt “the VA saved my life” (58.3%).  Veterans 
appreciated that the VHA provided Veteran’s with the new HCV medication (e.g., “The VA 
basically saved my life.”).  Nonetheless, Veterans noted areas in need of improvement to 
maximize medication adherence within the VHA system (66.7%) (e.g., “More contact from a 
doctor or from a professional type of person through the course of the medication… I met with 
the doctor every two weeks, but that was quick.”). 
 Successful completion of the HCV treatment regimen resulted in decreased 
psychological distress and ability to re-engage in productive life activities and social 
relationships.  Bringing emphasis to these positive outcomes and experiences could promote 
medication adherence.  More contact with treatment team members could further improve 
DAA adherence. 
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Discussion 
 
Three qualitatively derived theoretical constructs involving the experiences of 
Veterans’ who successfully completed the new HCV medication trials elucidated factors that 
likely affected their medication adherence: burden of HCV, treatment engagement process, and 
positive outcomes.  Veterans described burdensome psychological distress, anxiety, and worry 
about having HCV and knowing about the progressively negative and ultimately fatal health 
consequences of the disease.  Learning about the more efficacious and tolerable non-interferon 
based medications, relative to prior medication options, gave Veterans hope they could lift 
these burdens and solidified their commitment to medication adherence.   
Veterans highlighted the importance of the treatment engagement process.  To them, it 
was a “no brainer” when providers presented to them the high efficacy rates, treatment 
simplicity, decreased length of treatment with a clear end point, and manageable side effects 
compared to interferon-based regimens.  Veterans looked forward to the ability to transform 
from “unhealthy” individuals to “healthy” people who had a chance to improve the quality of 
their lives.  
Provider, patient, and social/economic factors also facilitated medication adherence.  
Conditions facilitating adherence included: (1) having a strong working relationship with one’s 
provider based on trust, open communication, rapport, and respect; (2) harnessing patient-
driven strategies to promote adherence, such as incorporating the new medications into 
preexisting routines, using strategies to cope with medication side effects, and engaging 
regularly in positive self-talk and encouragement; (3) enlisting support from family and friends; 
and (4) heightening awareness about the cost of treatment and the opportunity provided to 
Veterans to receive the new HCV medications.  These conditions facilitating adherence support 
the previously published literature regarding the importance of implementing necessary 
support services (e.g., case management, transportation, housing), establishing rapport in the 
physician-patient relationship, providing adequate education to patients on potential effects of 
the medications, and developing patients’ positive pre-existing beliefs about the treatment 
(Edlin et al., 2001; Edlin et al., 2005; Gatti, Jacobson, Gazmararian, Schmotzer, & Kripalani, 
2009; Martin-Santos et al., 2008; Neame & Hammond, 2005; Sylvestre & Clements, 2007). 
Upon treatment completion, Veterans report feeling “free,” having a new chance at 
developing healthy relationships, an improved sense of purpose, and a desire to better their 
lives more broadly (e.g., eating healthier, exercising, being abstinent from substances of abuse, 
getting additional support for mental health or other medical issues).  Most Veterans reported 
satisfaction with the local VHA system’s structure and process for providing the new HCV 
treatment, and they expressed appreciation and gratitude to the VHA for giving them access to 
it.  In short, they felt they were given “a new lease on life” and wanted VHA healthcare 
providers to enhance services by providing Veterans prescribed the new HCV medications 
more professional medical contact throughout the course of treatment.  
 
Clinical Implications 
 
This study suggests that older, medically compromised HCV-positive Veterans view 
adherence to the new non-interferon DAAs as a fortuitous opportunity to improve their health 
and quality of life.  Veterans, their providers, and VHA policy makers are invested in achieving 
these life-changing positive outcomes (Veterans Health Administration, 2015).  To maximize 
adherence to these medications, providers should consider the individual medical, 
psychological, and social burdens stemming from having HCV, educate Veterans about the 
fatal progression of the disease if left untreated, and introduce information about the 
acceptability, feasibility, and efficacy of the new medications as a likely pathway to cure.  In 
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addition, given that many HCV-positive Veterans may hold negative views of HCV medication 
intervention based on their experiences in previous interferon-based treatment trials, 
distinguishing the new class of HCV medications from interferon-based treatment is 
particularly important.  Talking with Veterans in this manner about benefits of the new vs. 
older HCV medication options is consistent with motivational enhancement interventions that 
help patients explore and resolve their ambivalence toward behavior change (Magill et al., 
2014).  Providers should also help patients develop specific medication adherence plans that 
identify when patients might take their medications, how they will manage side effects, and 
how they will encourage themselves to continuously adhere to their regimens.  Establishing 
rapport, building trust, and being clear and honest with patients about their treatment plan, 
including addressing comorbid mental health and substance use issues, could further maximize 
patient medication adherence.  Moreover, underscoring the positive outcomes reported by other 
patients who have completed HCV medication trials, perhaps through testimonials, might lend 
additional confidence and hope to patients who want medical relief and physical and mental 
rejuvenation from HCV.  These various factors for promoting adherence underscore the 
importance of tailoring one’s interventions to the Veteran.  Depending on the Veterans and 
their presenting concerns, certain areas might be more of a focus for their purposes of 
maximizing their medication adherence. 
 Veterans in this study expressed gratitude for having access to the new and expensive 
DAAs and recommended even more contact with their providers during the course of 
treatment.  Specialty medical services may be limited in the amount of additional in-person 
contact that can be provided (Ford et al., 2012).  However, the VHA has many other clinical 
interventions that could support new HCV medication adherence, such as nurse case managers 
(Piette, Weinberger, Kraemer, & McPhee, 2001), health psychology consultations (Zeiss & 
Karlin, 2008), and telehealth interventions such as in-home messaging devices to monitor and 
prompt adherence (Darkins et al., 2008).  In addition, offering Veterans support groups 
(Perlman, Cohen, Altiere, Brennan, Brown, & Mainka, 2010), shared medical visits (Watts et 
al., 2009), and increased coordinated contact with other professionals involved in treatment 
(e.g., mental health or substance use provider) could further promote Veterans’ adherence to 
the new HCV medications. 
 
Current VHA Treatment for HCV 
 
The VHA, being the largest HCV care provider in the United States, has seen a rapid 
growth in the number of Veterans seeking treatment with the new DAAs (US Department of 
Veterans Affairs, 2015a; US Department of Veterans Affairs, 2015b; Veterans Health 
Administration, 2015).  Initially, the VHA reported that cost would not be a factor in 
prescribing the new medications (Ross, 2013), and all Veterans that wanted to be treated were 
to be treated (Veterans Health Administration, 2015).  With this recommendation, 17% of the 
VHA’s total pharmacy budget for fiscal year 2015 was allocated to the new HCV medications, 
totaling $696 million (Flynn, 2015).  Nearing the end of the fiscal year 2015, the VHA faced a 
budget deficit of more than $2.5 billion, largely attributable to the provision of these new 
medications (Daly, 2015; Oppel, 2015).  In response to this deficit, VHA began using the 
Choice Program to refer Veterans interested in HCV treatment to community, non-VHA 
providers (Daly, 2015).  Along with this outsourcing of treatment, only those Veterans with 
advanced liver disease are considered top priority for treatment (US Department of Veterans 
Affairs, 2015a; US Department of Veterans Affairs, 2015b; Wagner, 2015).  Given that this 
study was conducted with Veterans who received HCV treatment within the VHA, it remains 
unclear what effect the Choice Program will have on Veterans’ experiences being treated for 
HCV and their rates of adherence to the new HCV medications.  
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Study Limitations and Implications for Future Research 
 
This study’s generalizability is limited by its small sample size, focus on older Veterans, 
and implementation during the initial release of the new HCV medications.  Future studies 
should assess how younger and less medically ill Veterans with HCV view access and 
adherence to the new HCV medications.  Factors affecting their adherence may differ from this 
study’s sample in that the burdens of HCV may not have accumulated to the same degree.  
Likewise, with the advent of the Choice Program at the VHA and evolving healthcare insurance 
policies in the United States, the HCV treatment experiences of patients may change, which 
could influence medication adherence in different ways.  In addition, qualitatively examining 
factors that affect patients who did not complete their new HCV medication treatment trials is 
needed to identify new strategies to keep patients at risk for dropout in treatment.  Participants 
in this study had completed varying lengths of HCV treatment, including 12-, 16-, and 24-
weeks.  Future studies should consider how the length of treatment impacts adherence.  Finally, 
following a cohort of Veterans over a longer course of time post medication trial, identifying 
the accrued benefits, and conducting cost-benefit analyses could provide helpful information 
to Veterans and inform both healthcare policy and funding decisions as negotiated pricing and 
HCV treatment services continue to evolve in VHA and non-VHA care settings (American 
Association for the Study of Liver Diseases and the Infectious Diseases Society of America, 
2015).  
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